西妥珠單抗

西妥珠單抗(英語:cirmtuzumab;開發代號:UC-961),或譯次妥珠單抗,是一種抗ROR1人源化單株抗體[1][2]

西妥珠單抗
單株抗體
種類?
目標ROR1
臨床資料
其他名稱UC-961
法律規範狀態
法律規範
  • 研究性
識別資訊
CAS號1643432-38-5  checkY
UNII

它是一種處於早期臨床試驗中的實驗藥物,用於治療包括慢性淋巴細胞白血病(CLL)在內的多種癌症。[3][4]

參考資料

  1. ^ Choi MY, Widhopf GF, Castro J, Li H, Kidwell RL, Zhang SC, et al. Cirmtuzumab (UC-961), a First-in-Class Anti-ROR1 Monoclonal Antibody: Planned Interim Analysis of Initial Phase 1 Cohorts. Blood. 2015, 126 (23): 1736 [2024-03-10]. doi:10.1182/blood.V126.23.1736.1736. (原始內容存檔於2019-09-13). 
  2. ^ Researchers to test novel drug combination against toughest breast cancers. Medical Express. 2018-08-27 [2024-03-10]. (原始內容存檔於2023-04-06). 
  3. ^ Clinical trial number NCT03420183 for "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies" at ClinicalTrials.gov
  4. ^ 1st Mantle Cell Lymphoma Patient Dosed in Phase 1/2 Trial Testing Cirmtuzumab-Imbruvica Combo. Lymphoma News Today. 2018-05-18 [2024-03-10]. (原始內容存檔於2023-04-07).